AKBA vs AMGN

For growth investors, Akebia Therapeutics, Inc.

(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus 9. 9% for Amgen Inc. (AMGN). Amgen Inc. (AMGN) offers the better valuation at 23. 1x trailing P/E (14. 7x forward), making it the more compelling value choice. Analysts rate Akebia Therapeutics, Inc. (AKBA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Amgen Inc.

(AMGN) delivered a total return of +46. 2%, compared to -62. 2% for Akebia Therapeutics, Inc. (AKBA). Over 10 years, the gap is even starker: AMGN returned +156. 4% versus AKBA's -85. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 60β versus Akebia Therapeutics, Inc. 's 1. 14β — meaning AKBA is approximately 90% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Amgen Inc. (AMGN) carries a lower debt/equity ratio of 6% versus 7% for Akebia Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Akebia Therapeutics, Inc.

(AKBA) is pulling ahead at 47. 5% versus 9. 9% for Amgen Inc. (AMGN). On earnings-per-share growth, the picture is similar: Akebia Therapeutics, Inc. grew EPS 93. 7% year-over-year, compared to 88. 2% for Amgen Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus -2. 3% for Akebia Therapeutics, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus 9. 9% for AKBA. At the gross margin level — before operating expenses — AKBA leads at 83. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AKBA: 239.

0% to $4. 00.

In this comparison, AMGN (2.

9% yield) pays a dividend. AKBA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 2. 9% yield, +156. 4% 10Y return). Both have compounded well over 10 years (AMGN: +156. 4%, AKBA: -85. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AKBA is a small-cap high-growth stock; AMGN is a mid-cap quality compounder stock. AMGN pays a dividend while AKBA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.